Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 8/20 | 0.41 |
| ▸ | FLT1 | P17948 | 7/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911122 | 1.00 | P2RX7 (0.43) | P2RX7HTR2AHTR2CHTR2BCYP19A1 | |
| SCHEMBL26707490 | 0.85 | P2RX7 (0.47) | P2RX7HTR2AHTR2CHTR2BCDC7 | |
| SCHEMBL31362128 | 0.85 | P2RX7 (0.47) | P2RX7HTR2AHTR2CHTR2BCDC7 | |
| SCHEMBL9911121 | 0.85 | CYP19A1 (0.45) | P2RX7HTR2AHTR2CHTR2BCYP19A1 | |
| SCHEMBL31609625 | 0.81 | P2RX7 (0.43) | P2RX7HTR2AHTR2CHTR2BCDC7 | |
| SCHEMBL18926930 | 0.80 | HTR2C (0.49) | P2RX7HTR2AHTR2CHTR2BCDC7 | |
| SCHEMBL27572943 | 0.80 | FLT1 (0.43) | P2RX7HTR2AHTR2CHTR2BCDC7 | |
| SCHEMBL20284294 | 0.79 | P2RX7 (0.38) | P2RX7HTR2AHTR2CHTR2BCDC7 | |
| SCHEMBL24110439 | 0.78 | P2RX7 (0.47) | P2RX7HTR2AHTR2CHTR2BCDC7 | |
| SCHEMBL24110654 | 0.78 | P2RX7 (0.44) | P2RX7HTR2AHTR2CHTR2BCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | P2RX7 3705/4885HTR2A 2144/4885HTR2C 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.